BioAtla (BCAB) Current Leases (2021 - 2026)
BioAtla's (BCAB) quarterly Current Leases came in at $1.6 million in Q2 2026, up 95.03% on a YoY basis from $805000.0 in Q2 2025, and up 0.71% quarter-over-quarter from $1.6 million in Q1 2026.
Analysis
BioAtla (BCAB) Current Leases (2021 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Current Leases for 6 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Leases rose 95.03% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (up 95.03% YoY), and the FY2025 full-year result was $1.4 million, up 70.69% from the prior year.
- Current Leases improved to $1.6 million in Q2 2026 per BCAB's latest filing, from $1.6 million in the prior quarter.
- Across five years, Current Leases topped out at $1.7 million in Q2 2024 and bottomed at $554000.0 in Q1 2025.
- Historically, Current Leases has averaged $1.4 million across 5 years, with a median of $1.5 million in 2022.
- The sharpest annual moves came in 2025 and 2026: Current Leases plunged 63.29% in 2025, then soared 181.41% in 2026.
- Over 5 years, Current Leases stood at $1.5 million in 2022, then increased by 6.77% to $1.6 million in 2023, then slumped by 48.52% to $836000.0 in 2024, then jumped by 70.69% to $1.4 million in 2025, then grew by 10.02% to $1.6 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $1.6 million, $1.6 million, and $1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 11.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 12.38 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 1.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.57 Mn |
| Mar 31, 2026 | 1.56 Mn |
| Dec 31, 2025 | 1.43 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 805,000.00 |
| Mar 31, 2025 | 554,000.00 |
| Dec 31, 2024 | 836,000.00 |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 1.62 Mn |
| Sep 30, 2023 | 1.60 Mn |
| Jun 30, 2023 | 1.57 Mn |
| Mar 31, 2023 | 1.55 Mn |
| Dec 31, 2022 | 1.52 Mn |
| Sep 30, 2022 | 1.50 Mn |
| Jun 30, 2022 | 1.48 Mn |
| Mar 31, 2022 | 1.43 Mn |
| Dec 31, 2021 | 1.39 Mn |